Brief: Lantern Pharma Inc - Establishes Ai Center Of Excellence In Bengaluru
12/01/2026 14:08
Jan 12 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA INC - ESTABLISHES AI CENTER OF EXCELLENCE IN BENGALURU LANTERN PHARMA INC - HIRING INITIATED, EXPANSION EXPECTED TO BE CASH FLOW NEUTRAL LANTERN PHARMA INC - PHASE 1 FOCUSES ON AI-DRIVEN CANCER DRUG DEVELOPMENT LANTERN PHARMA INC - PHASE 2 FOCUSES ON MULTI-DISEASE EXPANSION AND REVENUE ACCELERATION Source text: ID:nBw1lXc0xa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments